Meta-analysis on effectiveness of hydroxyurea to treat transfusion-dependent beta-thalassemia

References

• Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 2000;283(15):2008–12.
   PubMed Web of Science ®Google Scholar
• Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7):e1000097.
   PubMed Web of Science ®Google Scholar
• Weels GA, Shea B, O'Connel D, Peterson J, Welch V, Losos M, et al. The Newcastle–Ottawa Scale (NOS) for assessing the quality of nonrandomized studies in meta-analyses. Available from: http://ohri.ca/programs/clinical_epidemiology/oxford.asp (accessed June 2014).
   Google Scholar
• OpenMeta[Analyst] 2012. Available from: http://www.cebm.brown.edu/open_meta (accessed June 2014).
   Google Scholar
• Bradai M, Abad MT, Pissard S, Lamraoui F, Skopinski L, de Montalembert M. Hydroxyurea can eliminate transfusion requirements in children with severe B-thalassemia. Blood 2003;102(4):1529–30.
   PubMed Web of Science ®Google Scholar
• Arruda VR, Lima CS, Saad ST, Costa FF. Successful use of hydroxyurea in beta-thalassemia major. N Engl J Med. 1997;336(13):964.
   PubMed Web of Science ®Google Scholar
• Ansari SH, Shamsi TS, Siddiqui FJ, Irfan M, Perveen K, Farzana T, et al. Efficacy of hydroxyurea (HU) in reduction of pack red cell (PRC) transfusion requirement among children having beta-thalassemia major: Karachi HU trial (KHUT). J Pediatr Hematol Oncol. 2007;29(11):743–6.
   PubMed Web of Science ®Google Scholar
• Ehsani MA, Hedayati-Asl A, Bagheri A, Zeinali S, Rashidi A. Hydroxyurea-induced hematological response in transfusion-dependent beta-thalassemia intermedia: case series and review of literature. Pediatr Hematol Oncol. 2009;26(8):560–5.
   PubMed Web of Science ®Google Scholar
• Karimi M. Hydroxyurea in the management of thalassemia intermedia. Hemoglobin 2009;33(1):S177–82.
   PubMedGoogle Scholar
• de Paula EV, Lima CS, Arruda VR, Alberto FL, Saad ST, Costa FF. Long-term hydroxyurea therapy in beta-thalassaemia patients. Eur J Haematol. 2003;70(3):151–5.
   PubMed Web of Science ®Google Scholar
• Taher A, Sheikh-Taha M. Hydroxyurea use in Lebanese patients with beta-thalassemia intermedia. J Pediatr Hematol Oncol. 2006;28(2):107.
   PubMed Web of Science ®Google Scholar
• Kattamis A. Treatment of thalassemia with hydroxyurea: an indispensable alternative therapy. J Pediatr Hematol Oncol. 2007;29(11):729–30.
   PubMed Web of Science ®Google Scholar
• Bohara VV, Ray S, Chakrabarti P, Ray SS, Nath UK, Chaudhuri U. Optimizing the dose of hydroxyurea therapy for patients with β-thalassemia intermedia (Hb E-β-thalassemia): a single center study from Eastern India. Hemoglobin 2014;38(1):44–8.
   PubMed Web of Science ®Google Scholar
• Dixit A, Chatterjee TC, Mishra P, Choudhry DR, Mahapatra M, Tyagi S, et al. Hydroxyurea in thalassemia intermedia – a promising therapy. Ann Hematol. 2005;84(7):441–6.
   PubMed Web of Science ®Google Scholar
• Italia KY, Jijina FJ, Merchant R, Panjwani S, Nadkarni AH, Sawant PM, et al. Response to hydroxyurea in beta thalassemia major and intermedia: experience in western India. Clin Chim Acta 2009;407(1–2):10–5.
   PubMed Web of Science ®Google Scholar
• de Franceschi L, Rouyer-Fessard P, Alper SL, Jouault H, Brugnara C, Beuzard Y. Combination therapy of erythropoietin, hydroxyurea, and clotrimazole in a beta thalassemic mouse: a model for human therapy. Blood 1996;87(3):1188–95.
   PubMed Web of Science ®Google Scholar
• Hoppe C, Vichinsky E, Lewis B, Foote D, Styles L. Hydroxyurea and sodium phenylbutyrate therapy in thalassemia intermedia. Am J Hematol. 1999;62(4):221–7.
   PubMed Web of Science ®Google Scholar
• Karimi M, Mohammadi F, Behmanesh F, Samani SM, Borzouee M, Amoozgar H, et al. Effect of combination therapy of hydroxyurea with l-carnitine and magnesium chloride on hematologic parameters and cardiac function of patients with beta-thalassemia intermedia. Eur J Haematol. 2010;84(1):52–8.
   PubMed Web of Science ®Google Scholar
• Dover GJ. Hemoglobin switching protocols in thalassemia. Experience with sodium phenylbutyrate and hydroxyurea. Ann N Y Acad Sci. 1998;850:80–6.
   PubMed Web of Science ®Google Scholar
• Elalfy MS, Adly AA, Ismail EA, Elhenawy YI, Elghamry IR. Therapeutic superiority and safety of combined hydroxyurea with recombinant human erythropoietin over hydroxyurea in young β-thalassemia intermedia patients. Eur J Haematol. 2013;91(6):522–33.
   PubMed Web of Science ®Google Scholar
• Mokhtar G, Tantawy AG, Abdel Moneim A, Waheed M. Thalassemia intermedia: an Egyptian experience. Haematologica 2009;94(2):241 abs. 0592.
   Google Scholar
• Loukopoulos D, Voskaridou E, Kalotychou V, Schina M, Loutradi A, Theodoropoulos I. Reduction of the clinical severity of sickle cell/beta-thalassemia with hydroxyurea: the experience of a single center in Greece. Blood Cells Mol Dis. 2000;26(5):453–66.
   PubMed Web of Science ®Google Scholar
• Koren A, Segal-Kupershmit D, Zalman L, Levin C, Abu Hana M, Palmor H, et al. Effect of hydroxyurea in sickle cell anemia: a clinical trial in children and teenagers with severe sickle cell anemia and sickle cell beta-thalassemia. Pediatr Hematol Oncol. 1999;16(3):221–32.
   PubMed Web of Science ®Google Scholar
• Rigano P, Manfré L, La Galla R, Renda D, Renda MC, Calabrese A, et al. Clinical and hematological response to hydroxyurea in a patient with Hb Lepore/beta-thalassemia. Hemoglobin 1997;21(3):219–26.
   PubMed Web of Science ®Google Scholar
• Loukopoulos D, Voskaridou E, Stamoulakatou A, Papassotiriou Y, Kalotychou V, Loutradi A, et al. Hydroxyurea therapy in thalassemia. Ann N Y Acad Sci. 1998;850:120–8.
   PubMed Web of Science ®Google Scholar
• Atweh GF, Loukopoulos D. Pharmacological induction of fetal hemoglobin in sickle cell disease and beta-thalassemia. Semin Hematol. 2001;38(4):367–73.
   PubMed Web of Science ®Google Scholar
• Rigano P, Rodgers GP, Renda D, Renda MC, Aquino A, Maggio A. Clinical and hematological responses to hydroxyurea in Sicilian patients with Hb S/beta-thalassemia. Hemoglobin 2001;25(1):9–17.
   PubMed Web of Science ®Google Scholar
• Panigrahi I, Dixit A, Arora S, Kabra M, Mahapatra M, Choudhry VP, et al. Do alpha deletions influence hydroxyurea response in thalassemia intermedia? Hematology 2005;10(1):61–3.
   PubMed Web of Science ®Google Scholar
• Voskaridou E, Kalotychou V, Loukopoulos D. Clinical and laboratory effects of long-term administration of hydroxyurea to patients with sickle-cell/beta-thalassaemia. Br J Haematol. 1995;89(3):479–84.
   PubMed Web of Science ®Google Scholar
• Italia KY, Jijina FF, Merchant R, Panjwani S, Nadkarni AH, Sawant PM, et al. Effect of hydroxyurea on the transfusion requirements in patients with severe HbE-beta-thalassaemia: a genotypic and phenotypic study. J Clin Pathol. 2010;63(2):147–50.
   PubMed Web of Science ®Google Scholar
• Singer ST, Kuypers FA, Olivieri NF, Weatherall DJ, Mignacca R, Coates TD, et al. Single and combination drug therapy for fetal hemoglobin augmentation in hemoglobin E-beta 0-thalassemia: considerations for treatment. Ann N Y Acad Sci. 2005;1054:250–6.
   PubMed Web of Science ®Google Scholar
• Fathallah H, Taher A, Bazarbachi A, Atweh GF. Differences in response to fetal hemoglobin induction therapy in beta-thalassemia and sickle cell disease. Blood Cells Mol Dis. 2009;43(1):58–62.
   PubMed Web of Science ®Google Scholar
• Maggio A, Rigano P, Renda D. Treatment with hydroxyurea in sickle cell/β-thalassemia; a long-term experience. Am Soc Hematol Blood (ASH Annual Meeting Abstracts) 2004;104: Abstract 1678.
   Google Scholar
• Saxon BR, Rees D, Olivieri NF. Regression of extramedullary haemopoiesis and augmentation of fetal haemoglobin concentration during hydroxyurea therapy in beta thalassaemia. Br J Haematol. 1998;101(3):416–9.
   PubMed Web of Science ®Google Scholar
• Karimi M, Cohan N, Pishdad P. Hydroxyurea as a first-line treatment of extramedullary hematopoiesis in patients with beta thalassemia: four case reports. Hematology 2015;20(1):53–7.
   PubMed Web of Science ®Google Scholar
• Kohli-Kumar M, Marandi H, Keller MA, Guertin K, Hvizdala E. Use of hydroxyurea and recombinant erythropoietin in management of homozygous beta thalassemia. J Pediatr Hematol Oncol. 2002;24(9):777–8.
   PubMed Web of Science ®Google Scholar
• Cario H, Wegener M, Debatin KM, Kohne E. Treatment with hydroxyurea in thalassemia intermedia with paravertebral pseudotumors of extramedullary hematopoiesis. Ann Hematol. 2002;81(8):478–82.
   PubMed Web of Science ®Google Scholar
• Cianciulli P, Caravita T, Sorrentino F, Sergiacomi L, Massa A, Amadori S. Hydroxyurea therapy in paraparesis and cauda equina syndrome due to extramedullary haematopoiesis in thalassaemia: improvement of clinical and haematological parameters. Eur J Haematol. 2000;64:426–9.
   PubMed Web of Science ®Google Scholar
• Zeng YT, Huang SZ, Ren ZR, Lu ZH, Zeng FY, Schechter AN, et al. Hydroxyurea therapy in beta-thalassaemia intermedia: improvement in haematological parameters due to enhanced beta-globin synthesis. Br J Haematol. 1995;90(3):557–63.
   PubMed Web of Science ®Google Scholar
• Chik KW, Lee V, Shing MMK, Li CK. Hydroxyurea treatment in beta-thalassemia intermedia. HK J Pediatric. 2006;11:20–1.
   Google Scholar
• Rashid S. Transfusion therapy as a sole treatment option in a thalassemia patient with acute paraplegia – a case report and review of literature. Pak J Neurol Sci. 2012;7(3):15–20.
   Google Scholar
• Choudhry VP, Lal A, Pati HP, Arya LS. Hematological responses to hydroxyurea therapy in multitransfused thalassemic children. Indian J Pediatr. 1997;64(3):395–8.
   PubMedGoogle Scholar
• Hajfath A, Khavaran K, Kariman N, Zakeri H, Nikfarjam S, Valaei N. Effects of hydroxyurea on hematologic parameters of patients with thalassemia intermedia. Pejouhandeh 2004;86(36):373–8.
   Google Scholar
• Yavarian M, Fayazi N, Rostamani N, Shamsaei M, Karimi M. Efficacy and side effects of hydroxyurea in patients with thalassemia intermedia. Med J Hormozgan Univ. 2007;11(2):109–14.
   Google Scholar
• Yavarian M, Karimi M, Bakker E, Harteveld CL, Giordano PC. Response to hydroxyurea treatment in Iranian transfusion-dependent beta-thalassemia patients. Haematologica 2004;89(10):1172–78.
   PubMed Web of Science ®Google Scholar
• Kosaryan M, Vahidshahi K, Karami H, Ehteshami S. Effect of hydroxyurea on thalassemia major and thalassemia intermedia in Iranian patients. Pak J Med Sci. 2009;25(1):74–8.
   Web of Science ®Google Scholar
• Karimi M, Darzi H, Yavarian M. Hematologic and clinical responses of thalassemia intermedia patients to hydroxyurea during 6 year of therapy in Iran. J Pediatr Hematol Oncol. 2005;27(7):380–5.
   PubMed Web of Science ®Google Scholar
• Alebouyeh M, Moussavi F, Haddad-Deylami H, Vossough P. Hydroxyurea in the treatment of major beta-thalassemia and importance of genetic screening. Ann Hematol. 2004;83(7):430–3.
   PubMed Web of Science ®Google Scholar
• Koren A, Levin C, Dgany O, Kransnov T, Elhasid R, Zalman L, et al. Response to hydroxyurea therapy in beta-thalassemia. Am J Hematol. 2008;83(5):366–70.
   PubMed Web of Science ®Google Scholar
• Bradai M, Pissard S, Abad MT, Dechartres A, Ribeil JA, Landais P, et al. Decreased transfusion needs associated with hydroxyurea therapy in Algerian patients with thalassemia major or intermedia. Transfusion 2007;47(10):1830–36.
   PubMed Web of Science ®Google Scholar
• Zamani F, Shakeri R, Eslami SM, Razavi SM, Basi A. Hydroxyurea therapy in 49 patients with major beta-thalassemia. Arch Iran Med. 2009;12(3):295–7.
   PubMed Web of Science ®Google Scholar
• Karimi M, Haghpanah S, Farhadi A, Yavarian M. Genotype-phenotype relationship of patients with β-thalassemia taking hydroxyurea: a 13-year experience in Iran. Int J Hematol. 2012;95(1):51–6.
   PubMed Web of Science ®Google Scholar
• Ansari SH, Shamsi TS, Ashraf M, Perveen K, Farzana T, Bohray M, et al. Efficacy of hydroxyurea in providing transfusion independence in β-thalassemia. J Pediatr Hematol Oncol. 2011;33(5):339–43.
   PubMed Web of Science ®Google Scholar
• Hashemi A, Abrishamkar M, Jenabzade AR, Eslami Z. Hydroxyurea can reduce or eliminate transfusion requirements in children with major and intermediate thalassemia. Iran J Blood Cancer 2009;1(4):147–50.
   Google Scholar
• Bordbar MR, Silavizadeh S, Haghpanah S, Kamfiroozi R, Bardestani M, Karimi M. Hydroxyurea treatment in transfusion-dependent β-thalassemia patients. Iran Red Crescent Med J. 2014;16(6):e18028.
   PubMed Web of Science ®Google Scholar
• Sachdeva A, Khanna K, Verma C, Kaul K, Dinesh A, Subash C. Hydroxyurea and termination of transfusion therapy in transfusion dependent thalassemics. The 44th American Society of Hematology Annual Meeting, 2002, Detroit, USA.
   Google Scholar
• Bradai M, Pissard S, Abad MT, Dechartes A, Ribeil JA, Landais P, et al. Evolution of transfusion requirement in Algerian thalassemic major (TM) and intermediate (TI) patients treated with hydroxyurea (HU). Am Soc Hematol Blood 2006;108:1588.
   Google Scholar